Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency

Setola, Emanuela; Monti, Lucilla D.; Lanzi, Roberto; Lucotti, Pietro; Losa, Marco; Gatti, Elisa; Galluccio, Elena; Oldani, Matteo; Fermo, Isabella; Giovannelli, Massimo; Bosi, Emanuele; Piatti, PierMarco

doi:10.1016/j.metabol.2008.07.024

Cited by 24 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in keeping with those obtained by Setola et al, who also reported that IGF-1 and ADMA levels were negatively associated after six months of growth hormone treatment [33]. …”

Section: Discussionsupporting

confidence: 93%

IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

Genre

López‐Mejías

Rueda-Gotor

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Like rheumatoid arthritis, ankylosing spondylitis (AS) is also an inflammatory disease associated with accelerated atherosclerosis and the presence of metabolic syndrome (MeS) features. AS patients often display osteoporosis as well as new bone formation. Insulin-like growth factor 1 (IGF-1) is a protein involved in both inflammation and bone metabolism. In the present study we assessed whether disease activity, systemic inflammation, MeS features, adipokines, and biomarkers of endothelial activation were associated with IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) levels in a series of 30 nondiabetic AS patients without CV disease undergoing TNF-α antagonist-infliximab therapy. All determinations were made in the fasting state, immediately before an infliximab infusion. Although no association of IGF-1 and IGFBP-3 levels with angiopoietin-2 or osteopontin was found, an inverse correlation between IGF-1 levels and asymmetric dimethylarginine (ADMA), an endogenous endothelial nitric oxide synthase inhibitor that impairs nitric oxide production and secretion promoting endothelial dysfunction, was found (r = −0.397; P = 0.04). However, no significant association was found between IGF-1 and IGFBP-3 levels and disease activity, systemic inflammation, metabolic syndrome features, or adipokines. In conclusion, in nondiabetic patients with AS undergoing periodic anti-TNF-α therapy, IGF-1 and ADMA are inversely correlated.

show abstract

“…Our results are in keeping with those obtained by Setola et al, who also reported that IGF-1 and ADMA levels were negatively associated after six months of growth hormone treatment [33]. …”

Section: Discussionsupporting

confidence: 93%

IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

Genre

López‐Mejías

Rueda-Gotor

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The reduction of waist/hip ratio has also been demonstrated by several prospective monocentric studies, which found an improvement of body composition especially in elderly GHD patients (>65 years) compared to the younger ones [45][46][47]. Furthermore, a after GH therapy [73,74].…”

Section: C Body Compositionmentioning

confidence: 91%

Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]

et al. 2015

View full text Add to dashboard Cite

Abstract. Adult growth hormone deficiency (GHD) is a well defined clinical condition, which is characterized by abnormal body composition, impaired physical activity and decreased quality of life. In addition, in recent years, growing interest has been shown towards cardiovascular risks in adult patients affected by GHD. In this regard, GHD is widely known to be associated with increased mortality, likely due to the increase of risk factors, such as central obesity, impaired lipid and glucose profiles and other less-known risk factors, such as inflammatory cytokines, endothelial dysfunction and oxidative stress. However, very few papers have recently discussed this topic. In this review, the aim is to clarify this issue by discussing evidence regarding the effects of adult GHD on metabolic and cardiovascular profiles.

show abstract

“…In a study with adults diagnosed with hypopituitarism, Krzyzanowska et al (4) showed that ADMA levels increased independent of GHD and well-recognized risk factors. In another study by Setola et al (5), ADMA levels were observed to decrease following a 6-month GH therapy in adults with GHD and in addition, there was a negative correlation between insulin-like growth factor-1 (IGF-1) and ADMA levels. It is expected that treatment approaches in pediatric applications for ADMA control will be implemented in the future (6).…”

Section: Introductionmentioning

confidence: 95%

Evaluation of Asymmetric Dimethylarginine (ADMA) Levels in Children with Growth Hormone Deficiency

Önder¹,

Aycan²,

Koca³

et al. 2014

Jcrpe

View full text Add to dashboard Cite

Objective: To investigate serum asymmetric dimethylarginine (ADMA) levels in children with isolated growth hormone deficiency (GHD) and to determine the effect of GH replacement therapy on these levels.Methods: 31 patients diagnosed with isolated GHD and 29 age-and sex-matched healthy children were enrolled in the study. Height, weight and waist circumference were measured in all subjects. Fasting serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3, glucose, insulin and lipid levels were evaluated. Serum ADMA levels were assessed using the enzyme-linked immunosorbent assay technique. The same evaluations were repeated on the 3rd and 6th months of treatment in 28 of the GHD cases.Results: There were no significant differences in ADMA levels between the patient and control groups [0.513±0.130 (0.291-0.820) µmol/L vs. 0.573±0.199 (0.241-1.049) µmol/L]. There was a positive correlation between serum ADMA and HbA1c levels in the control group. In the GHD cases, ADMA levels negatively correlated with high-density lipoprotein levels and positively correlated with low-density lipoprotein levels. There was also a significant increase in ADMA levels in patients receiving GH therapy compared to pre-treatment levels [serum ADMA level, 1.075±0.133 (0.796-1.303) µmol/L at the 3rd month and 0.923±0.121 (0.695-1.159) µmol/L at the 6th month of treatment]. There was a negative correlation between ADMA levels and homeostasis model assessment of insulin resistance values at the 6th month evaluation. There were no relationships between ADMA levels and age, sex, or pubertal state either before or during the treatment.Conclusion: Serum ADMA levels were found to be similar in patients with GHD and in healthy children. However, serum ADMA levels showed a significant increase in GHD patients following GH replacement therapy.

show abstract

Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency

Cited by 24 publications

References 36 publications

IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]

Evaluation of Asymmetric Dimethylarginine (ADMA) Levels in Children with Growth Hormone Deficiency

Contact Info

Product

Resources

About